Recently, Grand Pharmaceutical Group has been recognised by the Ministry of Science and Technology of China as a national talent introduction platform. Ever since our establishment, our Group has been actively building a highland for the gathering and innovation of domestic and overseas highly skilled talents, and has achieved positive progress in the introduction of talents.
In China’s biopharmaceutical industry, innovative local pharmaceutical companies have entered the global “deep sea” from domestic context. Based on the vision of comprehensive strengths, innovation leading and global expansion, our Group has built a high-end innovative research and development system and a gathering place for global talents’ innovation and entrepreneurship. Grand Pharmaceutical Group is advancing the global development of our innovative projects and implementing our transformation into a global, technology-based and innovative pharmaceutical company.
In order to provide a conducive research and development (R&D) environment for our talents, Grand Pharmaceutical Group has been deeply cooperating with global leading universities. Our Group has established a number of R&D centers around the world to promote the development and industrialisation of innovative drugs, generic drugs and medical devices.
As the main body of Grand Pharmaceutical Group in the pharmaceutical field, Grand Pharma Optics Valley R&D Center in Wuhan, China supports the medical research and development of high-end medical preparations. In Nanjing, China and Belgium, our Group has established technology platforms and R&D centres, focusing on the development of anti-tumour and anti-infective mRNA drugs. Our glycomics technology base is located in the R&D centre in Australia, focusing on the development of antiviral drugs. Yuanda Pharmaceutical Group, as a national talent introduction platform, will continuously build an innovation highland for global talents.
